Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Free Cash Flow (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Free Cash Flow data on record, last reported at -$18.8 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 14.99% year-over-year to -$18.8 million; the TTM value through Sep 2025 reached -$58.2 million, up 30.76%, while the annual FY2024 figure was -$72.0 million, 53.54% up from the prior year.
  • Free Cash Flow reached -$18.8 million in Q3 2025 per BTAI's latest filing, down from -$12.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$12.0 million in Q1 2025 and bottomed at -$52.4 million in Q1 2023.
  • Average Free Cash Flow over 4 years is -$27.1 million, with a median of -$26.9 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 60.92% in 2023, then skyrocketed 66.18% in 2024.
  • A 4-year view of Free Cash Flow shows it stood at -$38.6 million in 2022, then soared by 30.48% to -$26.9 million in 2023, then soared by 44.87% to -$14.8 million in 2024, then dropped by 26.86% to -$18.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$18.8 million in Q3 2025, -$12.6 million in Q2 2025, and -$12.0 million in Q1 2025.